Volume 26, Number 6—June 2020
Dispatch
Melioidosis in a Resident of Texas with No Recent Travel History, United States
Table
Drug | MIC, μg/mL | Result |
---|---|---|
Amikacin | >32 | R |
Ampicillin | >16 | R |
Ampicillin/sulbactam | >16/8 | R |
Aztreonam | >16 | R |
Cefazolin | >16 | R |
Cefepime | >16 | R |
Cefotaxime | 32 | R |
Cefoxitin | >16 | R |
Ceftazidime | 8 | S |
Ceftriaxone | >32 | R |
Cefuroxime | >16 | R |
Ciprofloxacin | >2 | R |
Gentamicin | >8 | R |
Ertapenem | >1 | R |
Meropenem | <1 | S |
Piperacillin/tazobactam | <16 | S |
Tobramycin | >8 | R |
Trimethoprim/sulfamethoxazole | <2/38 | S |
*R, resistant; S, susceptible.
Page created: May 19, 2020
Page updated: May 19, 2020
Page reviewed: May 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.